Literature DB >> 18483659

[Reversible posterior leukoencephalopathy syndrome in patients with immunosuppressive treatment: report of four cases].

Marta Hernández Ch1, Alicia Núñez F, Tomas Mesa L, Raúl Escobar H, Francisco Barriga C, Isidro Huete L.   

Abstract

Reversible posterior leukoencephalopathy syndrome (PLS) is characterized by headache, clouding of sensorium, visual disturbances and seizures. It is associated to hypertension, renal disease or immunosuppressive therapy. We report three males, aged 9, 12 and 16 years and one female, aged 5 years wih PLS associated to immunosuppressive therapy. All had seizures and three had headache and clouding of sensorium. One case was associated to an hypertensive emergency, one to liver failure and one to high tacrolimus levels. Magnetic resonance imaging showed lesions in the white matter in two patients and in the gray matter in the other two. The lapse between the start of immunosuppressive treatment and neurological symptoms ranged from 4 days to 6 months. All received antiepileptic drugs and immunosuppressive therapy was changed or decreased, with complete clinical recovery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483659     DOI: /S0034-98872008000100012

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

Review 1.  Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.

Authors:  Turun Song; Zhengsheng Rao; Qiling Tan; Yang Qiu; Jinpeng Liu; Zhongli Huang; Xianding Wang; Tao Lin
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

2.  Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.

Authors:  Julián Alejandro Rivillas; Stephania Galindo-Coral; Francisco Arias-Mora; Juan David Lopez-Ponce de Leon; Noel Alberto Florez-Alarcón; Pastor Olaya-Rojas; Juan Esteban Gomez-Mesa
Journal:  Case Rep Cardiol       Date:  2021-06-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.